QYNAPSE joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. DTRA plans to unite industry stakeholders to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.
QYNAPSE is pleased to sponsor the 106th Radiology Society of North America (RSNA) Annual Meeting. This year, QYNAPSE is presenting its latest technological advancements of its QyScore® medical device and will also showcase significant developments being made with its QyPredict® AI prediction technology, which is transforming central nervous system (CNS) clinical trials.
QYNAPSE appoints Matt Ullum, CPA, MBA as Chief Commercial Officer. In his new role, Matt assumes overall responsibility for both sales and marketing to accelerate the commercialization of QYNAPSE’s solutions globally. Matt is bringing over 15 years of experience spanning the global pharmaceutical and healthcare industries with a focus on central nervous system (CNS) disorders.
QYNAPSE will present results on QyPredict®, an AI prediction technology for patient selection in Alzheimer’s clinical trials, at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference. The software computes a cognitive decline risk score that can be used to enrich patient selection strategy with the aim to increase clinical trial success probability.
QYNAPSE today announces the acquisition of the Canadian company TRUE POSITIVE MEDICAL DEVICES Inc. (TPMD), a spin-off from the universities of McGill and Laval – to form the most advanced artificial intelligence (AI) platform in the field of imaging of brain diseases such as Alzheimer’s, Parkinson’s and multiple sclerosis.
Qynapse is strongly committed to innovation in the field of neurodegenerative diseases, particularly Alzheimer’s. “By combining the latest advances in neuroimaging and artificial intelligence algorithms, our solutions represent powerful tools for the diagnosis, disease monitoring and patient care for Alzheimer’s disease.”
These results confirmed that the use of a normative database for the interpretation of brain volumetric analysis, such as the QyScore® normative database, can improve the individual assessment of brain neurodegeneration in RRMS patients in the clinical routine setting.
Qynapse is excited to participate in MSVirtual2020 to share and discuss innovative and cutting-edge research in the field of Multiple Sclerosis (MS). The latest QyScore® validation and performance advances will be presented during the conference.
Qynapse is developing collaborations with European and US hospitals to support the diagnosis and monitoring of neurological complications of the virus, by providing QyScore® to automatically quantify brain MRI markers in COVID-19 patients for retrospective or prospective analyses.
QyScore®, the FDA-cleared and CE-marked software commercialized by Qynapse, confirms its value for the rapid measurement of brain atrophy and white matter hyperintensity in a clinical routine setting
Qynapse is a medical technology company that unlocks the potential of quantitative imaging and AI to optimize diagnosis, prognosis and longitudinal monitoring of patients with neurological diseases.
- Qynapse is pleased to sponsor #ACTRIMSForum 2021 – established to advance the research and clinical care of multipl… https://t.co/KJPuq7p83I14 hours ago
- As a founding member of the Decentralized Trials & Research Alliance @DTRAorg, we look forward to the collaboration… https://t.co/MkPrmyZmiu30 days ago
- Qynapse wishes you a Happy New Year 2021! We look forward to continue with exciting collaborations this year – to d… https://t.co/fMjDxQFUq851 days ago
- By advancing #decentralizedtrials we can make clinical trials more patient-focused, diverse and efficient, and leve… https://t.co/z8ck93CH7Y56 days ago
130, rue de Lourmel
75015 Paris – France